A $123 million financing has been raised for US-based Sling Therapeutics Inc, equipping it to carry out a Phase 3 trial of a candidate therapy for thyroid eye disease – an autoimmune disorder that can affect vision. Announced on 16 September, the Series C round was led by Forbion Capital Partners of the Netherlands with participation from new investor Sectoral Asset Management of Canada and existing investor TPG Life Sciences Innovations of the US.
GSK Plc is to pay up to $750 million to acquire a new asset for multiple myeloma – its latest move to expand its portfolio for blood cancers. The asset is a trispecific T cell engager, an engineered antibody linking the body’s immune cells directly to antigens on cancer cells. There are currently no approved trispecific T cell engagers, but authorisations have been granted to bispecific T cell engagers, a simpler version of the same therapy. Announced on 15 September, the deal includes an undisclosed upfront fee and milestone payments.
The following article is a summary of the 2026 financial forecasts for several publicly listed European biopharmaceutical companies.
Regulatory Strategy
How the US encourages rare disease drug development
By Darex Vera-Rodriguez and Michael Salgaller
Obesity Drug Review
Change is coming to the weight loss sector
By Peter Charlish
Interview
The role played by DEBRA Research in translational medicine
Public Policy
New EU regulation on the use of artificial intelligence
Research News
Shingles vaccine may protect heart
By Rosie Bannister
